NCH Healthcare Group, 1845 Veterans Park Drive, Suite 110, Naples, FL 34109, USA.
Curr Diab Rep. 2013 Jun;13(3):381-90. doi: 10.1007/s11892-013-0368-x.
A wealth of evidence has established that cholesterol-lowering statin drugs, widely used for the prevention of cardiovascular disease, do increase the risk of new-onset diabetes, possibly by impairing pancreatic beta cell function and decreasing peripheral insulin sensitivity. Groups at particular risk include the elderly, women, and Asians. The diabetogenic effect of statins appear directly related to statin dose and the degree of attained cholesterol lowering. Statins can cause hyperinsulinemia even in the absence of hyperglycemia and the potential mitogenic effects and implications of prolonged hyperinsulinemia are discussed. Suggestions are made as to how physicians might avert the hyperinsulinemic and diabetogenic effects of statin therapy in clinical practice, and modulate the detrimental effects of these drugs on exercise performance. Finally, long-term studies are needed to determine if the deleterious hyperinsulinemic and diabetogenic effects of statin therapy undermine the beneficial cardiovascular disease risk outcomes in various segments of the population.
大量证据表明,广泛用于预防心血管疾病的降胆固醇他汀类药物确实会增加新发糖尿病的风险,其可能机制为损害胰岛β细胞功能和降低外周胰岛素敏感性。尤其易发生这种情况的人群包括老年人、女性和亚洲人群。他汀类药物的致糖尿病作用似乎与他汀类药物剂量和胆固醇降低的程度直接相关。他汀类药物甚至在没有高血糖的情况下也可引起高胰岛素血症,而长期高胰岛素血症的潜在有丝分裂作用和影响也在讨论中。文中就如何在临床实践中避免他汀类药物治疗的高胰岛素血症和致糖尿病作用,并调节这些药物对运动表现的有害影响提出了建议。最后,还需要进行长期研究以确定他汀类药物治疗的有害高胰岛素血症和致糖尿病作用是否会降低此类药物在人群不同亚组中的心血管疾病获益风险。